Blinatumomab: A Targeted Antibody Therapy For Relapsed/Refractory B-Cell All
Blinatumomab, a monoclonal antibody, is indicated for relapsed/refractory B-cell ALL. It works by binding CD19 on B cells and CD3 on T cells, activating T cells and eliminating B cells. Administered via continuous IV infusion (9 mcg/m2/day) for 28 days, with a 14-day rest period, it can cause side effects like cytokine release syndrome, neurotoxicity,…